James Paul Kastenmayer - Aug 23, 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Signature
/s/ James Kastenmayer
Stock symbol
AGLE
Transactions as of
Aug 23, 2022
Transactions value $
$0
Form type
4
Date filed
8/25/2022, 07:39 PM
Next filing
Feb 24, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +130K $0.00 130K Aug 23, 2022 Common Stock 130K $0.68 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48 of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested.